피부과 위탁생산 시장 규모, 점유율, 동향 분석 보고서 : 제형별, 서비스별, 적응증별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Dermatology Contract Manufacturing Market Summary

The global dermatology contract manufacturing market size was estimated at USD 14.80 billion in 2024 and is projected to reach USD 36.78 billion by 2033, growing at a CAGR of 11.79% from 2025 to 2033. The market is driven by a rising incidence of skin diseases, increased demand for aesthetic and cosmeceutical products, and the expanding outsourcing of services by pharmaceutical and skincare companies.

Some other factors contributing to market growth include advancements in nanotechnology, AI-based analytics, and continuous manufacturing, which enhance formulation precision, scalability, and product quality.

In addition, increasing regulatory support, adherence to GMP standards, and improved market access are expected to drive the market growth. The regional expansion across the Asia Pacific and the Middle East, further fueled by cost advantages, skilled labor, and growing consumer demand, is also anticipated to propel the market forward. Thus, these factors are expected to drive the innovation-driven, efficient, and globally competitive dermatology manufacturing landscape.

In the global market, the rising incidence of skin diseases, including acne, psoriasis, eczema, and rosacea, is expected to drive demand for dermatology contract manufacturing. Furthermore, increasing pollution, stress, hormonal imbalances, and changing lifestyles are anticipated to contribute to the global burden of dermatological conditions. Thus, the increasing prevalence of pharmaceutical and cosmetic companies developing more effective topical, injectable, and biologic formulations is expected to boost market growth over the estimated time period. Such factors are expected to drive the market over the estimated time period.

Moreover, growing requirements for aesthetic and cosmeceutical products, driven by increasing consumer awareness of skincare, aging concerns, and a preference for non-invasive beauty treatments such as anti-aging creams, serums, dermal fillers, and skin-rejuvenation injectables, are further contributing to market growth. In addition, the trend towards personalized and premium skincare is encouraging brands to collaborate with the CDMOs for innovative, science-backed formulations and rapid product launches. Furthermore, the expansion of social media influence and the growth of middle-class populations in markets are expected to present new growth opportunities for dermatology-focused contract manufacturers across the globe.

Furthermore, growing trends towards personalized and premium skincare are reshaping the dermatology contract manufacturing market. Besides, most consumers are increasingly seeking solutions tailored to their skin type, genetics, and lifestyle, which is expected to drive the demand for customized formulations and advanced delivery systems. In addition, premium skincare products are increasingly featuring high-performance ingredients, clean-label formulations, and innovative textures that are gaining popularity across global markets. Furthermore, most CDMOs are leveraging data-driven formulation technologies, AI-based skin analysis, and precision manufacturing to support brands in developing dermatology and cosmeceutical products. This shift toward personalization, customer engagement, brand differentiation, and long-term growth opportunities within the dermatology manufacturing landscape is expected to drive the market over the estimated time period.

Global Dermatology Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global dermatology contract manufacturing market report based on dosage form, service, indication, end use, and region.

• Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
• Semi-Solid Formulations
  • Creams
  • Ointments
  • Gel
  • Others
• Liquid Formulations
  • Sprays
  • Foams
  • Dermal Injectables
  • Others
• Solid Formulations
• Transdermal Products
• Devices / Combination Products
• Others
• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Formulation Development
• Analytical Method Development
• Scale-Up & Process Validation
• Contract Manufacturing
  • Clinical / Batch Manufacturing
  • Commercial Manufacturing (CM)
• Packaging & Labelling
• Others
• Indication Outlook (Revenue, USD Million, 2021 - 2033)
• Acne
• Psoriasis
• Rosacea
• Alopecia
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Specialty Dermatology Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Dosage Form
  • 1.2.2. Service
  • 1.2.3. Indication
  • 1.2.4. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Botton-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Dermatology Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Dermatology Contract Manufacturing Market: Dosage Form Estimates & Trend Analysis

• 4.1. Dermatology Contract Manufacturing Market, By Dosage Form: Segment Dashboard
• 4.2. Dermatology Contract Manufacturing Market, By Dosage Form: Movement Analysis
• 4.3. Dermatology Contract Manufacturing Market Estimates & Forecasts, By Dosage Form, 2021 - 2033 (USD Million)
• 4.4. Semi-Solid Formulations
  • 4.4.1. Semi-Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. Creams
    • 4.4.2.1. Creams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Ointments
    • 4.4.3.1. Ointments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Gel
    • 4.4.4.1. Gel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Liquid Formulations
  • 4.5.1. Liquid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Sprays
    • 4.5.2.1. Sprays Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Foams
    • 4.5.3.1. Foams Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Dermal Injectables
    • 4.5.4.1. Dermal Injectables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Solid Formulations
  • 4.6.1. Semi-Solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Transdermal Products
  • 4.7.1. Transdermal Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Devices / Combination Products
  • 4.8.1. Devices / Combination Products Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Dermatology Contract Manufacturing Market: Service Estimates & Trend Analysis

• 5.1. Dermatology Contract Manufacturing Market, By Service: Segment Dashboard
• 5.2. Dermatology Contract Manufacturing Market, By Service: Movement Analysis
• 5.3. Dermatology Contract Manufacturing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 5.4. Formulation Development
  • 5.4.1. Formulation Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Analytical Method Development
  • 5.5.1. Analytical Method Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Scale-Up & Process Validation
  • 5.6.1. Scale-Up & Process Validation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Contract Manufacturing
  • 5.7.1. Contract Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.2. Clinical / Batch Manufacturing
    • 5.7.2.1. Clinical / Batch Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.3. Commercial Manufacturing (CM)
    • 5.7.3.1. Commercial Manufacturing (CM) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Packaging & Labelling
  • 5.8.1. Packaging & Labelling Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Dermatology Contract Manufacturing Market: Indication Estimates & Trend Analysis

• 6.1. Dermatology Contract Manufacturing Market, By Indication: Segment Dashboard
• 6.2. Dermatology Contract Manufacturing Market, By Indication: Movement Analysis
• 6.3. Dermatology Contract Manufacturing Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
• 6.4. Acne
  • 6.4.1. Acne Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Psoriasis
  • 6.5.1. Psoriasis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Rosacea
  • 6.6.1. Rosacea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Alopecia
  • 6.7.1. Alopecia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Dermatology Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 7.1. Dermatology Contract Manufacturing Market, By End Use: Segment Dashboard
• 7.2. Dermatology Contract Manufacturing Market, By End Use: Movement Analysis
• 7.3. Dermatology Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 7.4. Pharmaceutical & Biopharmaceutical Companies
  • 7.4.1. Pharmaceutical & Biopharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Specialty Dermatology Companies
  • 7.5.1. Specialty Dermatology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Others
  • 7.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Dermatology Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Australia
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. South Korea
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Middle East & Africa
  • 8.7.1. Middle East & Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Saudi Arabia
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Qatar
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Oman
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Akums Drugs & Pharmaceuticals Ltd.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Glamris Dermacare
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Lifevision Healthcare
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Allrite Group
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Medconic Dermaceutics
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Shinom Cosmeceuticals
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. WISDERM
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Marvex Pharma
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Servocare Lifesciences
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Zestwin Lifesciences
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Cledral Life Sciences
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Cosmenova
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Hanisan Healthcare
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives
  • 9.3.14. Thea Janus
    • 9.3.14.1. Company Overview
    • 9.3.14.2. Financial Performance
    • 9.3.14.3. Service Benchmarking
    • 9.3.14.4. Strategic Initiatives
  • 9.3.15. Genesis Biotec
    • 9.3.15.1. Company Overview
    • 9.3.15.2. Financial Performance
    • 9.3.15.3. Service Benchmarking
    • 9.3.15.4. Strategic Initiatives